HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
HeartSciences (HSCS) had its price target lowered by Ascendiant Capital Markets from $9.00 to $8.00. They now have a "buy" rating on the stock.
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center